A Phase 1 Trial of D2C7-IT in Combination with an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally via Convection-Enhanced Delivery Followed by Perilymphatic Injections of 2141-V11 and Assessment of the Tumor Monorai
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Exvade Bioscience Inc.
Start Date
June 11, 2024
End Date
May 31, 2027
Administered By
Duke Cancer Institute
Awarded By
Exvade Bioscience Inc.
Start Date
June 11, 2024
End Date
May 31, 2027